PTC Therapeutics: Sephience As A Major Growth Driver

2026-02-23 07:26:20 ET

PTC Therapeutics ( PTCT ) is entering a new phase of growth as newer products begin to replace older revenue sources. I believe the recent launch of Sephience, an oral therapy approved for the treatment of phenylketonuria (PKU), a rare genetic disorder that prevents patients from properly metabolizing the amino acid phenylalanine, could become the company's primary driver of revenue expansion over the next several years. Although recent financial comparisons are affected by the sale of Evrysdi royalties, the underlying business appears to be strengthening, which may not yet be fully reflected in the company's valuation....

Read the full article on Seeking Alpha

For further details see: